Get started

Financials · CPHI

China Pharma Holdings Inc. (CPHI) financials

For the twelve months ended Jun 30, 2026, China Pharma Holdings Inc. reported $3.91M of revenue and -$4.47M of net income.

Revenue, TTM
$3.91M
Revenue growth, YoY
-11.0%
Net income, TTM
-$4.47M
Net margin
-114.3%
Cash
$304.9K
P/S
5.96
Market cap
$23.3M
Annual revenue$4.14M
FY2016FY2025
Annual net income-$3.19M
FY2016FY2025
Annual free cash flow$88.9K
FY2016FY2025

CPHI revenue and earnings growth

CPHI revenueQ2 2026$948.3K

Quarter YoY
-7.5%
QoQ
-3.6%
FY YoY
-8.5%
5Y CAGR
-17.5%
10Y CAGR
-14.7%

CPHI revenue was $948.3K in fiscal Q2 2026 (ended Jun 30, 2026), down 7.5% from a year earlier and down 3.6% from the prior quarter. For the full fiscal 2025 it was $4.14M, down 8.5% from fiscal 2024. Compound annual growth was -17.5% over 5 years and -14.7% over 10 years. It rose in 0 of the last 10 fiscal years.

CPHI net incomeQ2 2026-$1.46M

CPHI net income was -$1.46M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$528.4K a year earlier. For the full fiscal 2025 it was -$3.19M, compared with -$4.74M in fiscal 2024.

CPHI EPSQ2 2026-$0.04

CPHI diluted EPS was -$0.04 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.74.

CPHI free cash flowQ4 2025$151.5K

Quarter YoY
-45.7%
10Y CAGR
-28.8%

CPHI free cash flow was $151.5K in fiscal Q4 2025 (ended Dec 31, 2025), down 45.7% from a year earlier. For the full fiscal 2025 it was $88.9K, compared with -$444.5K in fiscal 2024. Compound annual growth was -28.8% over 10 years.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$4.14M$4.53M$7.01M$8.10M$9.64M$10.87M$10.92M$12.33M$13.21M$15.57M
Cost of revenue$4.28M$6.51M$7.29M$8.60M$9.29M$8.91M$9.44M$10.36M$10.74M$12.35M
Gross profit-$131.9K-$1.99M-$281.1K-$493.9K$349.3K$1.95M$1.48M$1.97M$2.47M$3.22M
Research and development$280.9K$283.9K$240.1K$185.9K$319.0K$378.0K$229.6K$172.4K$90.5K$366.0K
Selling, general and admin$2.45M$1.78M$1.47M$1.89M$1.65M$1.82M$2.29M$1.95M$2.02M$2.27M
Operating income-$3.24M-$4.59M-$2.75M-$3.55M-$2.86M-$2.58M-$20.41M-$10.45M-$18.68M-$8.16M
Interest expense$27.3K$27.4K$30.6K$434.6K$542.0K$294.2K$321.7K$451.3K$539.3K$849.6K
Pre-tax income-$3.19M-$4.74M-$3.08M-$3.97M-$3.40M-$2.87M-$20.70M-$10.86M-$19.15M-$8.87M
Income tax--------$110.0K$122.6K$308.2K
Net income-$3.19M-$4.74M-$3.08M-$3.97M-$3.40M-$2.87M-$20.70M-$10.75M-$19.28M-$9.18M
EPS, basic-$0.74-$2.71-$0.91-$3.78-$0.74-$0.07-$0.48-$0.25-$0.44-$0.21
EPS, diluted-$0.74-$2.71-$0.91-$3.78-$0.74-$0.07-$0.48-$0.25-$0.44-$0.21
Diluted shares----46.1M43.6M43.6M43.6M43.6M43.6M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$345.1K$626.9K$1.42M$2.03M$4.86M$957.7K$1.18M$2.46M$2.46M$2.67M
Receivables$241.4K$232.1K$504.4K$421.5K-$501.9K$635.4K$916.9K$2.29M$4.00M
Inventory$1.62M$2.27M$3.73M$2.95M$2.95M$3.71M$3.59M$5.05M$6.41M$7.31M
Current assets$2.35M$3.27M$6.00M$5.96M$9.09M$5.32M$5.58M$8.75M$12.29M$17.52M
Total assets$31.00M$14.89M$16.47M$17.78M$22.65M$21.12M$22.24M$45.38M$59.95M$78.52M
Current liabilities$7.40M$5.02M$6.82M$12.74M$10.51M$11.40M$10.05M$10.05M$9.23M$10.40M
Short-term debt$1.44M$1.14M$1.13M-------
Long-term debt----$5.25M-----
Total debt----$5.25M$5.24M$4.30M$6.54M$9.22M-
Total liabilities$8.26M$7.14M$9.01M$13.49M$16.63M$13.11M$13.00M$15.18M$16.88M$19.61M
Shareholders' equity$22.74M$7.75M$7.45M$4.29M$6.02M$8.00M$9.24M$30.20M$43.07M$58.91M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow$148.3K-$406.1K-$699.7K-$409.5K-$249.8K-$42.3K$608.3K$1.88M$841.2K$2.90M
Capital expenditures$59.3K$38.4K$11.5K$402.0K$438.1K$867.3K$136.0K$51.1K$136.5K$193.4K
Free cash flow$88.9K-$444.5K-$711.2K-$811.5K-$687.9K-$909.6K$472.3K$1.83M$704.7K$2.70M
Investing cash flow-$137.3K-$291.7K-$11.5K-$402.0K-$438.1K-$867.3K-$136.0K-$51.1K-$136.5K-$193.4K
Financing cash flow-$294.0K-$33.8K$73.1K-$1.77M$4.60M$624.2K-$1.73M-$1.98M-$1.48M-$6.02M
Depreciation and amortization$1.50M$2.62M$2.75M$2.70M$3.09M$2.68M$2.93M$3.26M$3.29M$3.08M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-8.5%-35.4%-13.5%-15.9%-11.3%-0.5%-11.4%-6.7%-15.1%-23.5%
Gross margin-3.2%-43.8%-4.0%-6.1%3.6%18.0%13.6%16.0%18.7%20.7%
Operating margin-78.2%-101.3%-39.2%-43.8%-29.7%-23.7%-186.8%-84.7%-141.4%-52.4%
Net margin-76.9%-104.6%-43.9%-49.0%-35.3%-26.4%-189.5%-87.2%-145.9%-59.0%
Free cash flow margin2.1%-9.8%-10.1%-10.0%-7.1%-8.4%4.3%14.8%5.3%17.4%
Return on equity-14.0%-61.1%-41.3%-92.6%-56.5%-35.8%-224.1%-35.6%-44.8%-15.6%
Return on assets-10.3%-31.8%-18.7%-22.3%-15.0%-13.6%-93.1%-23.7%-32.2%-11.7%
Current ratio0.320.650.880.470.860.470.560.871.331.68
Debt to equity----0.870.650.470.220.21-

Source: XBRL data China Pharma Holdings Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CPHI peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CPHI$3.91M-11.0%-$4.47M-114.3%$23.3M
LLY$86.46B+45.5%$27.58B31.9%$1.35T
JNJ$99.33B+7.8%$16.09B16.2%$675.03B
ABBV$66.01B+10.7%$10.34B15.7%$521.41B
MRK$67.38B+4.9%$2.45B3.6%$362.83B
NVS$54.53B+8.4%$13.98B25.6%$305.91B
AZN$58.74B+8.6%$10.22B17.4%$287.63B
ABT$48.23B+10.0%$4.70B9.7%$189.28B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$181.94B

CPHI FAQ

7 questions
  • What is CPHI revenue?
    China Pharma Holdings Inc. (CPHI) reported $3.91M of revenue for the twelve months ended Jun 30, 2026. That is down 11.0% from the year before. Revenue for fiscal 2025 was $4.14M.
  • Is CPHI profitable?
    No. China Pharma Holdings Inc. reported a net loss of $4.47M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does CPHI have?
    China Pharma Holdings Inc. reported $304.9K in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is CPHI revenue growing?
    China Pharma Holdings Inc.'s revenue changed -8.5% in fiscal 2025, to $4.14M. Its compound annual growth rate was -17.5% over 5 years and -14.7% over 10 years.
  • What is CPHI gross margin?
    China Pharma Holdings Inc.'s gross profit was $460.2K on $3.91M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 11.8%.
  • When did CPHI last report financial results?
    The latest statements here come from China Pharma Holdings Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.
  • Where does this CPHI financial data come from?
    Quantisnow builds these statements from the structured XBRL data China Pharma Holdings Inc. files with the SEC. It is provided for information only and is not investment advice.